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INTRODUCTION
Statement of the Problem
While significant progress has been made in the reduction of tobacco use in the
United States over the last decade (Centers for Disease Control and Prevention
[CDC], 2018b) the smoking prevalence rates among the socially and economically
disadvantaged populations remain high (CDC, 2018b). As a result, these
vulnerable populations carry a disproportionate economic, morbidity, and
mortality burden that is related to tobacco use (CDC, 2018b; Flocke, Hoffman,
Park, Birkby; Trapl et al., 2017). There is cost-effective, and evidence-based
treatment available for tobacco use dependence (Fiore et al., 2008; Stead,
Koilpillai, Fanshawe, and Lancaster, 2016), but aspects of that treatment are not
being delivered consistently to this population (Roberts, Kerr, & Smith, 2013;
Twyman, Bonevski, Paul, and Bryant, 2014). The purpose of this research is to
improve access to evidence-based behavioral health referrals and pharmacotherapy
for tobacco use dependence treatment for the vulnerable population served by the
federally qualified health clinic (FQHC) study clinic.
Background
With the inhalation of tobacco smoke, the body is exposed to more than 7000 toxic
chemicals and at least 70 carcinogens (American Cancer Society [ACS], 2017).
Some of the chemicals in and produced by burning tobacco and its additives
include nicotine, hydrogen cyanide, formaldehyde, lead, arsenic, ammonia,
radioactive uranium, benzene, carbon monoxide, and nitrosamines (United States
Department of Health and Human Services [USDHHS], 2014, ACS, 2017).
According to the American Lung Association (2019) State of Tobacco
Control Report, seven out of ten smokers wish to quit. Only 4 to 7 % of individuals
who attempt to stop smoking can do it “cold turkey” (Fiore et al., 2008). Getting
support from the healthcare provider, which includes counseling and medication,
doubles the chances for a successful quit attempt (ACS, 2018). For most smokers,
quitting is more than just willpower. On average, smokers may attempt to quit 611 times before they succeed (ACS, 2018).
A disproportionate burden in the vulnerable population. Despite the
progress in reducing smoking prevalence among the general population within the
United States (CDC, 2018), there exist significant healthcare disparities related to

tobacco use within certain populations in the United States (CDC, 2018b). Health
equity is defined in public health as the opportunity for all to “reach their full health
potential” (Whitehead & Dahlgren, 2006). According to Whitehead & Dahlgren
(2006), no one should be prevented from achieving this potential because of their
social position or social circumstance. Health equity as it relates to tobacco use
prevention and control is the opportunity for everyone to live a healthy, tobaccofree life, regardless of their level of education, sexual orientation, the job they have,
gender identity, whether they have a disability, or their race (CDC, 2015). Best
Practices (Whitehead & Dhalgren, 2006) recommends that to further reduce
overall tobacco use and second-hand exposure, attention to reducing tobacco use
and second-hand exposure in the population groups that bear the greatest burden
of tobacco use will help to reduce those disparities.
Prevalence and factors related to tobacco use in vulnerable
populations. In general, the smoking prevalence rates are higher among males,
those who are aged 25-64 years, individuals with less education, American
Indians/Alaska Natives, individuals of multiple races, uninsured, or insured
through Medicaid, individuals living below the poverty line, those who have a
disability, and individuals who are part of the lesbian, gay, bisexual, or transgender
community, and those who are living in the Midwest or the South (CDC, 2018b).
In 2016, the estimated percentage of adults (18 years and older) who are currently
smoking is at 15.5% (37.8 million), in striking contrast to prevalence rates with
vulnerable populations (Jamal et al, 2018According to Jamal et al., (2018), the
prevalence rates in the U.S. (2016) as it relates to race/ethnicity were: American
Indians and Alaskan Natives-31.8%, Asians (non-Hispanic)-9.0%, Blacks (nonHispanic)-16.5%, Hispanics-10.7%, Multiple Races (non-Hispanic)-25.2%, and
Whites (non-Hispanic)-16.6%.
According to the CDC’s Morbidity and Mortality Weekly Report (2015),
adults in the United States who are on Medicaid or are uninsured engage in tobacco
use at a rate of more than double of those adults who have either private health
insurance or are on Medicare. In comparison, only 12.9% of adults who have
private insurance smoke, and only 12.5% of Medicare recipients currently smoke
(CDC, 2015). According to the 2014 National Health Interview Survey (NHIS),
29.1% of Medicaid patients smoke, and 27.95 % of uninsured patients currently
smoke.
Health Risks Associated with Tobacco Use. There is no safe way to use
tobacco products. (ACS, 2017). About 50% of those smokers, if they continue to
smoke, will die because of their tobacco use, and they will die younger than nonsmokers (ACS, 2017). Tobacco use shortens the lives of male smokers by 12
years, and female smokers by 11 years (ACS, 2017). The American Cancer
Society (2017) reports that the use of tobacco increases cancer risk, and accounts
for thirty (30%) of all cancer deaths. Smoking tobacco is responsible for eighty

(80%) of all lung cancer deaths in the United States. While the risk for lung cancer
is significant and especially hard to treat, the risk for other cancers is also high (i.e.
mouth, larynx, pharynx, esophagus, kidney, cervix, liver, bladder, pancreas,
stomach, colon, and myeloid leukemia). Also, the risks for lung cancer and other
related diseases are increased for those individuals who are exposed to secondhand smoke (ACS, 2017). Cigar smokers are four to ten times more likely to die
secondary to cancers of the throat, larynx, esophagus, and mouth than individuals
who do not smoke (ACS, 2017).
Economic costs attributable to tobacco use. Because of the higher
smoking prevalence rates among vulnerable populations, there is also a significant
economic impact that is attributable to tobacco use. The global cost for tobacco
use accounted for nearly 2% of the world’s gross domestic product in 2012, or
$1,436 billion US dollars, according to the World Health Organization (WHO)
(Boyles, 2017, Goodchild, 2017). A global economic impact analysis was
completed by WHO and the World Bank (Goodchild, 2017). That study measured
both the direct cost of smoking (i.e. hospital admissions and treatment) and the
indirect costs using the validated human capital methods (HCM) which calculates
the value of human capital loss due to death and illness. Global working years lost
due to smoking-related illness and death totaled 26.8 million. The indirect costs
of smoking-related diseases were estimated to be $1,014 billion (US dollars) with
disability accounting for $357 billion and death accounting for $939 billion
(Goodchild, 2017).
Smoking-related costs totaled an estimated 3% of the gross domestic
product of the United States (Goodchild, 2017). For every smoking attributed
death, there are at least thirty (30) people that live with a smoking-related disease.
Smoking-related illness in the United States results in more than $300 billion per
year, which is nearly $170 billion in direct medical care for adults and more than
$256 billion in lost productivity (ACS, 2018).
Positive health and economic impact of smoking cessation. According
to the National Cancer Institute (NCI) Smokefree.gov website (2019), within hours
of quitting tobacco use, the individual’s blood pressure and heart rate decrease,
and the risk of heart attack is reduced. Risks for hearing loss, and overall vision is
decreased, and night vision is improved. The risk for premature aging and
excessive wrinkling of the skin is reduced. Risks for the formation of harmful
blood clots is reduced. The individual can expect a brighter smile, less shortness
of breath with exertion, stronger bones, reduction of serum cholesterol, and
normalization of white blood cells following smoking cessation (National Cancer
Institute [NCI], 2019). For an extensive list of positive health outcomes following
smoking cessation (See Appendix A for a complete list of positive health
outcomes) (WHO, 2014.).

Tobacco use prevention and control activities are public health’s “best buy”
(CDC, 2018a). These activities are considered comprehensive and have
demonstrated that they reduce the number of people who currently smoke, and
therefore reduce tobacco-related health care costs and hospitalizations by up to $55
for every dollar spent on prevention (CDC, 2018a).
Cost-effective and evidence-based treatment recommended. The
Department of Health and Human Services, Public Health Service published
updated clinical practice guidelines in Treating Tobacco Use and Dependence
(Fiore et al., 2008) that provided evidence-based and cost-effective treatment (See
Appendix B for the 10 Key Recommendations). As part of those guidelines, they
utilized the conceptual framework of motivational interviewing and recommended
the 5A’s (See Appendix C) and 5 R’s (See Appendix D) models to be used by
healthcare providers when treating tobacco dependence. In 2014, the United States
Preventive Services Task Force reiterated the guidelines as “A” recommendations
for the reduction of tobacco use (See Appendix E). Implementation of these
recommendations is generally incorporated in the tobacco use prevention and
control activities at the global, national, and state-level (WHO, 2017, USDHHS,
2013, Chung, Lavender and Bayakly, 2016). In 2018, Barua, and Rigotti et al.,
published the American Academy of Cardiology Expert Consensus Decision
Pathway on Tobacco Cessation Treatment (Appendix F) providing their
recommendations for treatment of cardiac patients that are currently using tobacco
that also reflect similar recommendations as the original guidelines.
Global and national approach to the tobacco use epidemic. Tobacco
use remains the world’s leading cause of premature mortality and smoking-related
morbidity (WHO, 2015). The American Cancer Society web site (Drope et al.,
2018) estimates that there are currently one billion smokers in the world. Tobacco
use is the leading cause of preventable mortality because of the association of
smoking-related diseases that result in nearly six million deaths per year (WHO,
2015). To gain some perspective, the combined mortality annually from
tuberculosis, human immunodeficiency virus (HIV), and malaria are less than the
tobacco-related deaths per year (WHO, 2011). Based on current projections,
tobacco use is expected to be responsible for eight million deaths or 10% of global
deaths by 2030. The strong association with tobacco use and lower socioeconomic
status continues to generate increasing health disparities at both the global and
national levels (Van Schayck et al., 2017). To confront this epidemic, the United
Nations General Assembly in 2011 adopted a declaration that committed the
members to a 25% reduction in premature mortality from non-communicable
diseases by 2025, which includes a 30% reduction in smoking prevalence (United
Nations, 2011). Tobacco control policies generated by the World Health
Organization (WHO, 2015), an agency of the United Nations, as developed by the
Framework Convention on Tobacco Control (FCTC) has been successful in

reducing smoking prevalence. Article 14 of the FCTC addresses the treatment of
tobacco dependence and insists that cessation support is an essential component of
treatment and works synergistically with the other tobacco control measures
(WHO, 2015). While many of the public health efforts recommended by WHO
has been successful in preventing individuals from commencing the use of
tobacco, many individuals who are addicted to the nicotine in tobacco that will
need the assistance of a healthcare provider to stop smoking tobacco (Van Schayck
et al., 2017). WHO (2015) has suggested that primary care is the most suitable
healthcare setting for providing advice and treatment for smoking cessation.
According to Raw, Mackay, and Reddy (2016), only 15% of the world’s
population has access to this smoking cessation support. According to WHO
FCTC: High Level of Ratification, Low Level of Full Implementation Report
(WHO Regional Office for Europe, 2018), the WHO Framework Convention on
Tobacco Control (FCTC) is a legally binding treaty for cost-effective tobacco
control has nearly 50 countries (out of 53) who have committed to implementation
but still have not fully implemented the policies that they have agreed to in the
FCTC.
Significant strides have been made in the reduction of smoking and
tobacco use within the United States (CDC, 2018b). According to the CDC
(2018b), cigarette smoking among U.S. adults (aged 18 years or above) has
declined from 20.9% in 2005 to 17.9% in 2016. In 2015, an estimated 52.8
million adults were former smokers. Of the 36.5 million current adult smokers,
49.2 percent stopped smoking for a day or more in the preceding year because
they were trying to quit smoking completely (ALA, 2018, CDC, 2015).
The findings from the National Health Interview Survey (NHIS) indicate
that the percentage of adults who have quit smoking increased from 50.8% in
2005 to 59% in 2016 (CDC, 2018). According to the CDC (2018b), more
people are quitting, and those that remain smoking have decreased the number
of cigarettes smoked. Cigarette smoking among U.S. adults has been reduced
by 50% since 1964, according to the CDC (2018b). While this gradual decline
is to be celebrated, tobacco use remains the leading cause of preventable
morbidity and mortality (CDC, 2018b) in the United States. Smoking-related
diseases result in premature deaths of more than 480,000 Americans per year
(CDC, 2018b), or about 1 in 5 deaths (USDHHS, 2014). For every person who
dies from tobacco use, there are 30 Americans who suffer from smokingattributable diseases (CDC, 2018b). According to Jamal et al., (2018), more
males smoke than females, ages 25-64 years constitute the largest group of
smokers, the lower the education the higher the smoking prevalence, and those
individuals who live below the poverty level are more likely to smoke. Jamal
et al. (2018) report that adults that smoked daily, eighty-seven percent had tried
their first cigarette by 18 years of age, and ninety-five percent by the age of 21.

According to the American Lung Association (2018), nearly 9.3% of high
school students use tobacco, and 2.3% of middle school students are current
smokers of tobacco.
In Healthy People 2020 (USDHHS, 2013), the overall goal regarding
tobacco use was to reduce illness, disability, and death related to tobacco use
and secondhand smoke exposure in the United States. Objective TU-4 sets the
target at 8% (adult smokers who have successfully stopped smoking within the
past 6 months to 1 year), and 80% (of adults aged 18 years and older who have
attempted to stop smoking in the past 12 months) (USDHHS, 2013).
Healthcare system change objectives included increasing Medicaid coverage
for nicotine dependency pharmacotherapy that was evidence-based (TU-9).
The target for increasing tobacco cessation counseling in office-based
ambulatory care settings (TU-10.1) is 21.1% (% of visits among current tobacco
users who are adults being seen at office-based ambulatory care settings who
had tobacco cessation counseling provided or ordered during that visit). Also,
the objectives included increasing tobacco cessation counseling in substance
abuse, and mental health care settings (USDHHS, 2013).
Georgia and North Central Public Health Districts approach to
tobacco use. Based upon updated 2018 data from the CDC’s Behavioral Risk
Factor Surveillance System (BRFSS), The United Health Foundation (2018) has
determined that the State of Georgia’s overall smoking prevalence rate is 17.1%.
According to the 2016 Georgia Tobacco Use Surveillance Report (Chung,
Lavender, & Bayakly, 2016), the State of Georgia had 1.35 million adult smokers,
over 10,000 adults in Georgia die from smoking-related diseases per year, and the
economic costs are staggering with 3.2 billion dollars in lost productivity and 1.8
billion dollars in healthcare costs attributed to smoking based upon the CDC’s
Behavioral Risk Factor Surveillance System 2014 data. Other significant
conclusions from the 2016 Georgia Adult Disparities in Tobacco Use Report
(Chung, Lavender & Bayakly, 2016) included: In Georgia, smoking prevalence is
highest among non-Hispanic whites (19.3%, or 785,000) followed by Hispanics
(15.6%, 92,000), and non-Hispanic blacks (14.6%, 201,000) (Chung et al, 2106).
Smoking cigarettes are 6 times more likely among adults without a high school
education (31.8%) than with a college education (5.6%). Adult males (40.7%) that
do not have a high school education are more likely to smoke in comparison to all
other groups (Chung et al., 2016). Approximately 25% of Georgia adults do not
have any type of health insurance (Chung et al., 2016). Forty-five (45) percent of
non-Hispanic white smokers and twenty-nine (29) percent of non-Hispanic Black
smokers do not have any form of health insurance. Based upon the 2014 BRFSS
data, cigarette smoking is higher among individuals who are employed in
construction (32.2 %), food preparation (31.4%), and transportation and material

moving occupations (27.8%) (Chung et al.,2016). Almost 21% of stroke patients
in Georgia are current smokers (Chung et al., 2016). For patients who have had a
heart attack, 22% were current smokers. And one-fourth (25%) of adults who
suffer from asthma continue to smoke (Chung, et al., 2016). According to
Gvinianidze and Tsereteli (2012), about 72,500 potential years of life were lost in
Georgia during the year 2008 due to active smoking, with most of the burden being
related to cancer and cardiovascular diseases.
The estimated number of adult smokers for the North Central Public Health
District is 54,000, and the smoking prevalence is 16.8 percent according to the
2014 BRFSS data (Georgia Department of Health, 2016). The North Central
Health District is comprised of Baldwin, Bibb, Crawford, Hancock, Houston,
Jasper, Jones, Monroe, Peach, Putnam, Twiggs, Washington and Wilkinson
counties (North Central Public Health, 2019).
FQHC clinics in the U.S. and FQHC study clinics prior approach.
While tobacco use poses serious health risks for the general population, the density
of high-risk populations that are treated at FQHC clinics results in a smoking
prevalence rate of 25.8, an average of 5.2% percentage points (Range, -4.9 to 20.9)
higher among FQHC clinics (Flocke et al., 2017).
According to Flocke et al., (2017), Georgia has 23 FQHCs serving a total
of 156,980 patients, and 36,182 of those patients currently smoke. This equates to
an average smoking prevalence rates within FQHC clinics in Georgia at 25.3%
(Range: 6.0-48.8) in comparison to 22.4% tobacco use in Georgia’s population.
Before the commencement of the study, an FQHC study clinic smoking
prevalence report was generated from the electronic health record for 2017 and 6
months of 2018. Based on the data provided by FQHC EHR, it is estimated that
the smoking prevalence rate was 32.5% (K. Arispe [personal communication,
April 18, 2018]). These statistics support the premise that the population
frequently served at the FQHC study clinics are at a higher risk for ongoing
tobacco abuse without the usual ability to access evidence-based smoking
cessation treatment secondary to lower socioeconomic status, and lack of
insurance.
The FQHC clinics had previously implemented changes in the EHR to
include prompts on smoking status and desire to quit smoking in response to the
national guidelines for the treatment of tobacco use dependence. The support staff
routinely asks incoming patients a series of evidenced-based questions to
determine tobacco use status, the level of nicotine dependence (based on the
frequency of smoking cigarettes), and validate tobacco cessation pharmacotherapy
listed in current medications. When the patient is seen by the health care provider,
and the system identifies the patient as a current smoker, the anticipation is that
the provider will enter the advice to quit under preventive counseling and whether
the patient desires to make a quit attempt. Within the preventive and counseling

sections of the electronic health record, several options are provided to select
evidence-based treatment to facilitate easy documentation of smoking cessation
treatment. Informal discussions with healthcare providers before the intervention
provided valuable information by the identification of barriers perceived by the
administrative and healthcare providers. When the higher prevalence rates were
demonstrated for the administrative and healthcare provider team, there was an
interdisciplinary organizational effort to work to reduce the smoking prevalence
rate at the FQHC study clinic and agreement to support the efforts of the principal
investigator to develop an intervention that may have the potential to increase the
delivery of evidence-based smoking cessation treatment and indirectly reduce the
smoking prevalence rate for their vulnerable populations.
Significance of the Problem
Research about smoking cessation treatment is extensive. Upon careful analysis
of systematic reviews and meta-analysis studies, national guidelines have been
generated for tobacco use dependence treatment. Evidence-based interventions
were recommended in those guidelines, but subsequent studies demonstrate that
the translation of those guidelines into clinical practice is not occurring
consistently.
The research highlights that the assistance with and arranging for
behavioral health referrals and smoking cessation pharmacotherapy (as
recommended by national guidelines) is where the deficiencies remain in the
delivery of evidence-based smoking cessation treatment. Additional studies have
researched factors that impact the full implementation of those guidelines,
including the lack of education and training, lack of resources, and concerns about
the cost of the counseling and pharmacotherapy (Colomar et al., 2014; Himelhoch
et al., 2014; Van Schayck et al., 2017).
Gaps in the literature included studying the impact of a multicomponent
intervention (focused educational training and provision of quick reference
materials) on the referral and prescribing behaviors of healthcare providers in an
FQHC setting within a southeastern state.
According to Flocke et al. (2017), the prevalence rates for tobacco use in
federally qualified healthcare clinics (FQHC) averages 5.2 percentage points
higher (range -4.9 to 20.9) when compared to the general population of the United
States. As an FQHC, the healthcare clinicians at the study clinic have the
responsibility to provide smoking cessation treatment to its vulnerable
populations. They need to address the FQHC study clinics estimated the smoking
prevalence of 32% (K. Arispe [personal communication April 18, 2018]) to further
reduce the health disparities that are occurring in their population because of the
tobacco use epidemic in Middle Georgia.

Even a small improvement in smoking cessation referrals and treatment can
yield substantial improvements in quality of life for those patients who can stop
smoking.
Purpose Statement
The purpose of this research is to improve access to evidence-based
behavioral health referrals and pharmacotherapy for tobacco use dependence
treatment for the vulnerable population served by the FQHC study clinic
healthcare clinicians. The goal of this study is to find a solution for the lack of
consistent delivery of “Assistance” and “Arrangement” (5 A’s Model) of the U.S
Public Health Guidelines for Tobacco Use Dependence Treatment (Fiore, et al.,
2008) as it relates to behavioral health referrals and pharmacotherapy for smoking
cessation.
Specific aim 1. To develop a multicomponent intervention for the FQHC
clinician participants that is based upon the conceptual framework of Kotter’s
Change Theory (Kotter, 2014) assists in the translation of evidence to clinical
practice and addresses the identified barriers to implementation of the clinical
guidelines as it relates to behavioral health referrals and pharmacotherapy.
Specific aim 2.
Measure the impact of the provision of the
multicomponent intervention to determine if it has improved the delivery of
behavioral health referrals and pharmacotherapy by comparing the data before the
intervention to the data retrieved at eight weeks following the intervention and
determining if there is a statistical or clinical significance. Participants will be
encouraged to utilize the evidence-based 5A’s and 5 R’s Model to deliver smoking
cessation therapy.
Specific aim 3. Measure the percentage of current smokers who have been
advised to quit that are motivated to make a quit attempt and compare with other
research studies that have ascertained the percentage of current smokers that wish
to make a quit attempt.
Specific aim 4. Describe the sample characteristics and correlate the
individual characteristics to improvement in the delivery of behavioral health
referrals and pharmacotherapy for smoking cessation.
Clinical Questions
Clinical question 1. How does education about smoking cessation and the
provision of quick reference materials affect referrals to behavioral counseling and
prescribing smoking cessation pharmacotherapy with healthcare providers at
federally qualified healthcare centers in one southeastern state within an eightweek period?
Clinical question 2. What percentage of Self-Identified Current Smokers
(SICS) expressed a willingness to attempt quitting?

Clinical question 3. What provider characteristics are associated with
increased smoking cessation referrals/treatment?
Definitions and Terms
Federally Qualified Healthcare Center (FQHC) Study Clinic.
Community-based outpatient clinics that have qualified for specific
reimbursement systems under Medicare and Medicaid to provide primary care
services in underserved areas (Health Resources and Services Administration
[HRSA], 2018).
Current smoker. “An adult who has smoked 100 cigarettes in his or her
lifetime, and who currently smokes cigarettes.” (CDC, 2019).
Smoking status of the patient. A designation that is recorded in the
electronic health record of the FQHC study clinic based upon several questions
about cigarette smoking as a current smoker, former smoker, never smoked, and
smoking status unknown.
Participant. A healthcare clinician (i.e. MD, DO, NP, PA) providing
primary care during the designated periods at one of the five participating FQHC
study clinics and have agreed to voluntarily participate (signed informed consent),
and who were present at the provider meeting when the intervention occurred.
Principal Investigator (PI) was not a participant.
Multi-component intervention [Phase 1]. An intervention comprised of
an educational presentation on July 25, 2018, provision of a quick reference
handbook to the participants, and revisions in the electronic health record system
to facilitate documentation of the qualifying smoking cessation treatment.
Pre-Intervention data collection [Phase 2]. Patient data retrieved from a
retrospective electronic health record review at the FQHC study clinic for 8 weeks
pre-intervention for each participant.
Post-Intervention data collection [Phase 3]. Patient data retrieved from
a retrospective electronic health record review at the FQHC study clinic for 8
weeks post-intervention for each participant.
Candidate. Patients that are identified in the electronic health record as
current smokers, who have been counseled to quit within the last 24 months, who
are interested in quitting smoking, and have not been provided quitline or handouts
in 12 months.
Compliance. Data retrieved from retrospective chart review that
documented any of the following as it relates to behavioral health referrals: 1)
Healthcare provider counseling for smoking cessation, or 2) Healthcare provider
referral to mental health clinician for face-to-face or group supportive counseling,
or 3) Referral to smoking cessation classes, or 4) Referral to the Georgia Tobacco
Quitline by the provision of telephone numbers or initiating an electronic or fax

referral, or 5) Provision of written materials that provided community resources
for behavioral health for smoking cessation therapy.
Data retrieved from retrospective chart review that documented any of the
following prescriptions ordered, recommended, or referred to an entity to which
they could obtain the following medications or smoking cessation medications
identified as current medications in the electronic health record for the visit in
which the patient is seen when deemed eligible: 1) Bupropion SR (Zyban,
Wellbutrin); 2) Nicotine gum; 3) Nicotine inhaler; 4) Nicotine Lozenge; 5)
Nicotine Nasal Spray; 6) Varenicline (Chantix); 7) Or any combination thereof.
Data retrieved from retrospective chart review that documented the
following is considered compliance: 1) behavioral health referral or 2)
pharmacotherapy for smoking cessation or 3) provided either or both.
Current smokers who expressed a desire to quit. Self-identified current
smokers who have expressed a desire to quit smoking or agreed to attempt to quit
smoking or was provided with a behavioral health referral or pharmacotherapy for
smoking cessation (implied consent).

Literature Review and Synthesis
The literature review will provide a summary of the clinical practice guidelines
Treating Tobacco Use and Dependence (Fiore, et al., 2008), the Tobacco Smoking
Cessation in Adults, Including Pregnant Women: Behavioral and
Pharmacotherapy Interventions published by the U.S. Preventive Services Task
Force (2015), and the American College of Cardiology (ACC) Expert Consensus
Decision Pathway on Tobacco Cessation Treatment (Barua, R. S. and Rigotti, N.
A., et al., (2018). Studies demonstrating the efficacy of behavioral counseling and
pharmacotherapy for smoking cessation (Fiore et al., 2008, Papakadis et al., 2016,
Piper et al, 2018) will be included in the review. Studies reviewed suggest primary
care providers are uniquely positioned to deliver effective tobacco cessation
treatment with a brief intervention using the 5 A’s and 5 R’s model as
recommended by Fiore, et al. (2008). The provision of the evidence-based
treatment using these models by primary care providers results in higher smoking
cessation quit rates (Fiore et al., 2008; Stead, Koilpillai, Fanshawe, and Lancaster,
2014). However, the literature suggests that referrals for behavioral health and
prescriptions for smoking cessation treatment were not being consistently
delivered (Twyman, Bonevski, Paul, and Bryant, 2014). The literature review
includes studies that identified the perceived barriers by health care providers to
the delivery of this treatment and identified factors (i.e. healthcare provider
characteristics, education) that improved the delivery of the evidence-based

smoking cessation treatment (Colomar et al., 2014; Himelhoch, Riddle &
Goldman, 2014). And finally, the review of literature includes a summary of
Kotter’s Theory of Organizational Change.
A review of the literature was performed using the following databases:
CINAHL Complete, CINAHL Plus with Full Text, Cochrane Database of
Systematic Reviews, MEDLINE with Full Text, Psychology and Behavioral
Sciences Collection, and Google. Keywords used in the literature search included:
tobacco use, tobacco cessation, primary care, theories of behavior change, health
professionals.
Evidence-Based Treatment for Tobacco Use Dependence and Its Delivery
This section of the literature review will provide a summary of the clinical
practice guidelines (Fiore, et al., 2008), the recommendations for tobacco smoking
cessation published by the U.S. Preventive Services Task Force (2015), and the
American College of Cardiology decision pathway for providing tobacco cessation
treatment (Barua, R. S. and Rigotti, N. A., et al., (2018). Studies demonstrating
the efficacy of behavioral counseling and pharmacotherapy for smoking cessation
(Fiore et al., 2008, Papakadis et al., 2016, Piper et al, 2018) will be included in the
review. The literature review also suggests that primary care providers are
uniquely positioned to deliver this evidence-based treatment and that the
interventions recommended result in more successful quit attempts and increased
smoking abstinence (Fiore et al., 2008). Studies will be included in the literature
review that suggests that the evidence-based treatment recommended is not being
delivered consistently (Twyman, Bonevski, Paul, and Bryant, 2014).
Clinical Guidelines. Treating Tobacco Use and Dependence (Fiore, et al.,
2008), was published by the U.S. Department of Health and Human Services,
providing clinical practice guidelines for tobacco cessation treatment (See
Appendix B for the 10 key recommendations). Fiore et al. (2008) strongly suggest
that effective tobacco interventions require coordinated interventions on the part
of clinicians, and health care systems and the environment should foster and
support tobacco intervention as an essential component of healthcare delivery.
Fiore et al. (2008) also recommend that clinicians should be provided the training
and support to assist in the delivery of consistent, effective interventions to assist
their patients in smoking abstinence. Fiore et al. (2008) conclude that the most
effective way to get healthcare providers to intervene is to provide them with the
multiple evidence-based treatment options, provide institutional support for them
to use those treatments, and create the environment where a failure to intervene is
not within the standard of care.
In Chapter 3 Clinical Interventions for Tobacco Use and Dependence
(Fiore et al., 2008), the guidelines provide the rationale for healthcare providers to

make treatment of tobacco use a clinical priority: 1) Clinicians can make a
difference even with minimal intervention (less than three minutes); 2) there is
growing evidence that smokers that receive this advice and assistance are reporting
greater satisfaction with their healthcare, and 3) it is cost-effective. Fiore et al.
(2008) recommend the provision of this treatment with the use of the 5A’s and the
5 R’s Model. For the patient who is unwilling to quit, Fiore et al. (2008)
recommend that the clinician use motivational interviewing techniques as
delineated by the 5 R’s Model: 1) relevance, 2) risks, 3) rewards, 4) roadblocks,
and 5) repetition. Fiore et al. (2008) provided evidence that suggested that the use
of the 5 R’s increases future quit attempts.
Preventive Services Recommendations for Tobacco Smoking
Cessation. In 2015, the United States Preventive Services Task Force published
the Tobacco Smoking Cessation in Adults, Including Pregnant Women: Behavioral
and Pharmacotherapy Interventions recommended that healthcare providers
determine the tobacco status of all adults, advise them to stop using tobacco, and
provide them with behavioral interventions and the FDA approved
pharmacotherapy for smoking cessation. Subsequently, a research plan has been
developed to study the effectiveness of smoking cessation interventions (USPSTF,
2018) which may be instrumental in the development of updated treatment
guidelines (See Appendix E for the recommendations).
Tobacco Cessation Treatment Decision Tree. American College of
Cardiology (ACC) Expert Consensus Decision Pathway on Tobacco Cessation
Treatment (Barua, R. S. and Rigotti, N. A., et al., (2018) provided a comprehensive
tobacco cessation treatment decision-making tree with the acknowledgment that
consistent delivery remains a significant challenge (See Appendix F for the
decision-making tree).
Research Suggesting that Combinations of Pharmacotherapy May be
Effective. A more recent study (Piper et al., 2018) suggested behavioral health
interventions and combinations of pharmacotherapy were more effective when
compared to the usual care (10 minutes of in-person counseling, 8 weeks of a
nicotine patch, and referral to quitline services) at 4, 8, 16 and 26 weeks to
abstinence-optimized treatment (3 weeks of pre-quit mini-lozenges, 26 weeks of
nicotine patch and mini-lozenges, three in-person and eight phone counseling
sessions and 7-11 automated calls to prompt medication use). Key outcomes were
self-reported along with biochemically confirmed 7-day point prevalence.
Unique Position to Deliver Tobacco Dependence Treatment. Primary
care providers are in a unique position for helping tobacco users. If all primary
care providers routinely ask about tobacco use and advise tobacco users to stop,
they have the potential to reach more than 80% of all tobacco users per year; trigger
40% of cases to make a quit attempt; and help 2-3% of those receiving brief advice
quit successfully (WHO, 2014). The research (Fiore et al., 2008) suggests that this

brief intervention by healthcare clinicians during a patient’s routine visit can
provide a cost-effective, and evidence-based treatment for tobacco dependence.
According to Danesh, Paskett, and Ferketich (2014), healthcare providers in
primary care can make significant contributions to the reduction of the smoking
prevalence rates of their patients. Patients who are advised to quit smoking are 1.6
times more likely to do so upon the advice of a healthcare provider (Danesh et al,
2014; Wray, Funderburk, Acker, Wray & Maisto, 2018).
Lack of Consistent Delivery. The research suggests that the delivery of
evidence-based treatment is not occurring consistently (Papadakis, 2016).
Assisting and arranging for the provision of behavioral health and
pharmacotherapy for smoking cessation is an essential component of the evidencebased treatment (Fiore et al., 2008). According to Kruger et al. (2016), current
cigarette-only smokers who visited a health professional in the last 12 months selfreported that only 6.3% had received both counseling and medication for smoking
cessation within the past year. Also, Kruger et al. (2016) reported that 3.8% was
referred to a smoking cessation class or program, 3.7% were referred to one-onone counseling and 2.6% were referred to a telephone quitline. Based upon their
conclusions, current cigarette-only smokers who reported receiving all 5 A’s
during a recent clinic visit were more likely to use counseling, medication, or a
combination of counseling and medication, compared to smokers who received
one or none of the 5 A’s components.
With the enactment of the Medicare Access and CHIP Reauthorization Act
(2015), healthcare providers are now routinely documenting smoking status and
the provision of advice to quit (CMS, 2018). However, assistance with and
arranging for behavioral counseling, medications, programs, and other supports for
smoking cessation treatment is suboptimal (Roberts et al., 2013; Stead et al., 2016).
Guidelines for tobacco use dependence are readily available for healthcare
providers to assist in the provision of evidence-based treatment for smoking
cessation. Increasing the number of health care providers that deliver the evidencebased, brief interventions for tobacco use prescribed by the Public Health Service
Clinical Practice Guideline will expose more tobacco users to evidence-based
treatments and will result in more successful quit attempts and tobacco abstinence
(Fiore et al., 2008, USPSTF, 2014, Barua et al., 2018, Piper et al., 2018). These
guidelines and recommendations include the benefits of assistance with and
arranging for behavioral health and pharmacotherapy for smoking cessation.
However, the research suggests that is not being done with consistency. Hence, the
importance of reviewing the literature that identifies the barriers that are perceived
by healthcare providers that interfere with the successful delivery of this treatment.
Theoretical Framework
In the award-winning 8-Step Process for Leading Change (1996), Kotter
described a methodology that provides a process for implementing successful

change in organizations. This 8-Step process is delineated in the following
paragraphs.
Creating a sense of urgency. The first step in the process is creating a
sense of urgency (Kotter, 2014). He suggests that people need to see and feel the
need for change and that your actions and behaviors (not just your words) must
communicate that need for change. Without that sense of urgency, he states that
the change is doomed for failure.
Building a guiding coalition. The second step is building a guiding
Coalition (Kotter, 1996) in which he suggests that the traditional hierarchical
structure of most companies cannot quickly adjust to the constantly changing
environment that can enable it to take advantage of new opportunities or
challenges. He recommends that a coalition of effective people within the
organization guide the changes, coordinate it, and communicate its activities
(Kotter, 2014).
Formulate a strategic vision and initiatives. The third step is to
formulate a strategic vision and initiatives. This is important to demonstrate how
the change is different from the past, and by tying the initiatives directly to the
vision (Kotter, 2014).
Enlist a volunteer Army. The fourth step is to enlist a volunteer army
because it is only when large numbers of people buy-in and understand the urgency
to drive change that large-scale change can occur (Kotter, 2014). Without
additional volunteer help, the efforts are limited.
Remove Barriers. The fifth step is to enable action by removing barriers
which he states that by removing barriers inefficiencies in the process will provide
the freedom to work and generate long-lasting impact (Kotter, 2014).
Enable Short Term Wins. The sixth step is to enable short term wins by
recognizing and communicating results early on and often that track progress and
energizes volunteers to continue persisting (Kotter, 2014).
Sustain acceleration. The seventh step is to sustain acceleration by
pressing harder with the first successful results and being relentless with ongoing
change until the vision has been realized (Kotter, 2014).
Institutionalize the Change. The eight-step in the process is to
institutionalize the change with the articulation of the connections between the new
behaviors and the success of the organization and continue until the old habits are
replaced (Kotter, 2014).
This 8-step process developed by Kotter (1996, 2014) was used as the
framework for the development of the design of the study, the educational
presentation, the development of the quick reference materials provided to the
healthcare providers, and the dissemination of the results of the study. Data was
provided during the educational presentation that demonstrated a 33% smoking

prevalence at the FQHC study clinic which is substantially higher than the general
population. The international, national, and state targets for reduction in smoking
prevalence were provided to demonstrate the lack of compliance with those goals
to create a sense of urgency. The principal investigator met with administrative
staff, and incorporated staff responsible for quality improvement to ensure that we
built a strategic coalition to determine what type of research would be beneficial
to the FQHC study clinic. An information technology expert, with specialized
knowledge in retrieving data and managing the electronic health record at the study
clinic, was recruited to assist in the project. Analysis of the documentation of the
patient’s current smoking status, advice given to quit smoking, and the provision
of the smoking cessation treatment. Frequent communication with the information
technology officer occurred, and initial data was shared with the study clinic
administrative staff resulting in energizing the individuals involved. Once the
results were obtained, and the analysis was completed, communication of the
information occurred at the monthly provider meeting to provide important
feedback.

Methodology
Project Description
This is a translational research project that was designed to address the need for
improving the delivery of evidence-based smoking cessation treatment for a
specific clinical setting within a specific geographical area. An educational
intervention was delivered utilizing Kotter’s change theory along with the
provision of quick reference materials. In additional several changes were made
to the electronic health record to provide prompts to support provider
documentation of smoking status and smoking cessation interventions.
The purpose of this study was to determine the impact of a multi-component
intervention on behavioral health referrals for smoking cessation treatment and/or
the number of prescriptions for smoking cessation pharmacotherapy by healthcare
providers during visits in five (5) federally qualified healthcare clinic in the
southeast.
Setting
The clinics were all located in two separate cities approximately 90 miles
from a large southeastern metropolitan city. All clinics were operated by the same
business entity. These clinics are designated federally qualified healthcare clinics
(FQHCs) responsible for the provision of primary healthcare for vulnerable

populations for their area. Sixteen healthcare providers are employed at the clinics
[4 MD’s, 1 DO, and 11 APRN’s (including part-time APRN who is the PIC for
this study)]. There is numerous support staff that is tasked with the registration,
and provision of care during the patient's visit. Medical Assistants are responsible
for requesting and entering smoking status information of the patient into the
electronic healthcare upon arrival and entering verification of the current
medication list.
Population and Sample
The population is healthcare clinicians that provide primary health care at
FQHCs. A convenience sample was recruited from the providers at the FQHC
study clinics located at five different locations. Most providers agreed to
voluntarily participate. Even though the primary investigator (PI) was a provider
at the clinic, there was no participation in the study by the PI. All participants who
commenced the study continued to participate until its completion.
Protection of Human Subjects
The Georgia College and State University and the Middle Georgia State
University Institutional Review Board approved this research proposal. Also,
approval of the research proposal was sought from the Executive Director and
Medical Director of the federally qualified healthcare clinic where the study was
to be conducted. All participants were given oral and written information about
the study and provided a consent form to be signed (see Informed Consent as
Appendix G).
The paper surveys collected at the meeting will remain in the possession
of the PI and will be placed in a locked file cabinet drawer and retained for one
year. After one year, the surveys will be shredded to ensure confidentiality and
discarded securely. Data files that contain any protected health information will
be maintained for three years in a password protected electronic file maintained by
the FQHC study clinic. Any data will only be reported in the aggregate form for
any publication or dissemination. Any data file placed on PI’s personal computer
will be devoid of any patient names or medical record numbers and will also be
password protected. If not in the personal possession of the PI, will be maintained
in a locked cabinet.
Data Collection Procedures
The data collection for this study was completed in three phases using a
retrospective medical chart review.
An information technology expert
incorporated the required prompts into the EHR and ran the reports to obtain
compliance data. Phase I data collection occurred during the intervention with the
participant characteristics questionnaire. Phase II data collection was collected
immediately following the recruitment of the participants and consisted of a
retrospective electronic medical chart review of all patients seen by the participants

for the period of eight- weeks before the intervention. Phase III data collection
was retrieved by a retrospective electronic chart review for all patients seen by
participants during the eight- weeks following the intervention.
Smoking Prevalence Rate for FQHC Study Clinic. Once IRB approval
was received, aggregate data were retrieved from the FQHC study clinics (5
clinical practices) electronic health records to determine the total number of adult
(18 years of age or older) patients seen for 2017 and determine the total number of
adults who were identified as current smokers for 2017 to ascertain the smoking
prevalence rate for this FQHC study clinic.
Phase 1. Following the educational intervention, all healthcare provider
participants were asked to complete a demographic questionnaire (See Appendix
H). It is estimated that the length of time to complete was approximately 10
minutes or less. The additional time for the participants to complete the brief
interventional counseling and treatment may have added approximately 10 minutes
to the length of the office visit, which did not excessively burden either the
healthcare provider participant or the patient during the visit.
Phase 2. Following the intervention, data was collected from the EHR for
all patients seen by each participant to determine the number of patients who were
candidates to receive the qualifying behavioral and pharmacotherapy smoking
cessation treatment and the number that received the above for the time eightweeks before the intervention. The percentage of current smokers that received
the qualifying treatment was calculated by dividing that number by the number of
patients seen by that provider. An aggregate percentage for all participants was
also calculated for this period. Also, data was collected to determine the number
of current smokers who were willing to make a quit attempt.
Phase 3. Upon completion of the Post Intervention period (8 weeks after
intervention), the same data using the same variables were retrieved from the
electronic health record for all the participants individually for the eight weeks after
the intervention. The individual and aggregate percentages were also calculated for
this period. The difference in percentages between these two periods was used for
comparison regarding the delivery of “qualifying treatment” to eligible current
smokers by healthcare provider participants.
Intervention
The multi-component intervention was developed based upon Kotter’s
theory of individual and organizational change (Kotter, 2014) and the identified
barriers and factors that impacted the consistent delivery of the evidence-based
smoking cessation treatment. The multicomponent intervention was comprised of
an educational intervention that provided healthcare providers with evidence-based
smoking cessation treatment, the design, background and methodology of the
proposed study, quick reference smoking cessation materials, and the

programming changes made to the electronic health records to facilitate easy
documentation for the provision of qualifying behavioral health and
pharmacotherapy for smoking cessation.
Educational Intervention. The purpose of the educational intervention
was to address identified barriers in published studies (i.e. lack of education and
training regarding the delivery of smoking cessation treatment, concern about the
cost of pharmacotherapy, lack of resources, etc.) and based upon Kotter’s steps of
success in leading change (Kotter, 2014) within organizations (See Appendix I for
the content delivered at the educational intervention).
Quick Reference Materials. Materials were collected, copied and placed
in a notebook by PI to provide a permanent reference book that could be quickly
accessed by the participant during a patient’s visit that would refresh their memory
about the specific data, information, community resources, and where
documentation will be required to ensure accurate data retrieval for the study (See
Appendix I for the content included in those notebooks).
Changes Made to FQHC study clinic electronic health care record. The
following changes were made to the EHR to improve the ease of documentation
for the provision of behavioral health referrals and documentation of
pharmacotherapy for smoking cessation treatment. These changes were discussed
at the provider meeting.
Instrumentation
No instruments were used to obtain data for this study. Participants
completed a short demographic questionnaire with questions about race, gender,
type of provider, years of practice, smoking status, and age group.
Variables
Clinical Question 1. Before-After is a binary variable with the following
values: 0=Phase II Pre-intervention Period (8 weeks before) and 1= Phase III Post
Intervention Period (8 weeks after). Candidate is a binary variable created by
transformation, that indicates if the patient was a candidate for checking to
determine if they were referred with the following values: 0=No and 1= Yes.
Compliant is a categorical variable that indicates if the candidate had a referral for
tobacco cessation treatment (either counseling and/or pharmacotherapy) with the
following values: 0=No, 1=Yes, and 3=NA-Patient was not a candidate.
Compliance Percentage is a transformational continuous ratio variable that
indicates the percentage of compliance by each provider.
Clinical Question 2. What percentage of Self-Identified Current Smokers
(SICS) expressed a willingness to attempt quitting?
Tobacco Users documented during the visit is a binary (YES/NO) variable
with the following values: 0=No and 1=Yes. Quit Interest is a categorical variable
that indicates the patient’s level of interest in quitting tobacco use with the
following values: 0=Interest in Quitting not Documented, 1=Not Ready to Quit,

2: Not Ready to Quit- found in Progress Notes, 3= Thinking about Quitting,
4=Thinking about Quitting-found in Progress Notes, 5= Ready to Quit. The
previous variables were transformed into a categorical variable Ready or
Considering Quitting with the following values: 0= Not Ready, 1: Ready to Quit
or Considering Quitting, 2= Unknown b/c interest not documented.
Clinical Question 3. What provider characteristics are associated with
increased smoking cessation referrals/treatment?
Age of Healthcare Participant. A continuous variable that indicates the
actual age of the participant on the date of the intervention.
Type of Provider. A nominal variable that indicates the type of provider.
Race. This is a nominal variable that indicates the race of the provider.
Years of Practice. A continuous variable that indicates the number of years
that the provider has been in practice on the date of the intervention.
Gender. A nominal binary variable that indicates the provider’s gender.
Smoking Status. A nominal variable that indicates what the smoking status
is for the provider.
Improvement. A transformational continuous variable that indicates if
there is an improvement in the percentage of patients that received the qualifying
treatment by the healthcare participant (Phase III treatment - Phase II treatment.
Plan for Data Analysis
Following a careful review of the clinical research questions that needed to
be answered, and determining the study design, a plan for data analysis was
devised. Clinical Question #1 is a causal question that seeks information about the
effect of an intervention on an outcome. Clinical Question #2 is seeking to
determine if the percentage of smokers that wish to quit within the FQHC study
clinic is similar to other national statistics and studies. Clinical Question #3 is a
relational question that seeks information about the relationship among variables,
and whether there is an association between the independent variable and the
dependent variable.
For each variable, the level of measurement will be determined and put into
SPSS Version 24. Each of the values associated with that variable will also be
entered. Excel files where the original data were downloaded into the SPSS
Version 24 data file. Only one individual was responsible for retrieving and
analyzing the data by a retrospective medical chart review after the algorithms
were developed to ensure continuity and reduce bias. Any duplicate files of
patients seen more than once during the designated period were removed. A
determination as to whether the variable is dependent or independent was done.
For any nominal data, graphic representations were created using pie graphs
showing frequencies and percentages, and descriptive statistics were run. For any
interval or ratio data variables, the descriptive statistics were run to demonstrate

the mean, median, and mode, range, percentiles, and levels of skewness and
kurtosis were run. A graphic histogram was created to determine if there was a
normal distribution, and statistical normality tests for small sample sizes were used
to determine if there was a normal distribution. Box Plots were also used to
determine normality, and to determine if there were significant outliers. Scatter
Plots were used to determine if there were any associations between the healthcare
participant characteristics (i.e. age, years of practice, gender, smoking status) and
the Improvement variable. For Clinical Question #1, descriptive statistics will be
used to describe the Difference continuous variable (Post-Intervention Percentage
– Pre-Intervention Percentage). In addition to the above, inferential statistics that
will be used is the Wilcoxon Ranked Test, if the results are non-parametric for the
paired sample testing.
For Clinical Question #2, simple descriptive statistics will be run to
determine the percentage of current smokers that wish to quit.
For Clinical Question #3, descriptive statistics will be used for all
independent and dependent variables. As stated above graphics will be used to
demonstrate the percentages in the form of pie graphs and histograms. For any
variables that are normally distributed, parametric inferential testing will be done
by Pearson’s Correlation. For the non-parametric testing required secondary to
lack of normality, Spearman’s Rho will be utilized for binomial variables and
ordinal variables. When correlating nominal categorical variables with continuous
ratio variables, chi-square analysis will be performed using SPSS Version 24 for
all the above.
TimeLine
The timeline for this study commenced after IRB approval. Phase 1 began
with the educational intervention and the recruitment of the participants. Phase 2
started following the educational intervention and retrospectively collected data
for 8 weeks before the intervention. Phase 3 commenced 8 weeks postintervention, and retrospectively collected data from the intervention until 8 weeks
post-intervention.
Budget
The monetary cost for this project is estimated to be $300.00 for printing
costs of the quick reference materials, and printing of dissemination materials. The
federally qualified healthcare clinic sponsored the costs of notebooks used for the
quick reference materials, and the costs of utilizing a programmer to retrieve
electronic health data. The APRN completing the intervention donated time for
preparing and delivering the educational intervention and preparation of the quick
reference notebooks. There were no additional costs that occurred during the study.
Conclusion

The project, setting, and population to be studied have been described in
detail. The protection of human subjects and the data to be collected has been
provided. All data collection procedures have been delineated for all phases of the
study. The multicomponent intervention has been described to provide an
overview of the content. The variables subject to statistical testing have been given
for each clinical question. The plan for data analysis using SPSS Version 24 has
been described, as well as the budget and timeline for the translational clinical
project.

Results
The healthcare participants were recruited using convenience sampling. Data was
gathered by retrospective medical record review after participants were recruited
to collect for pre-intervention and post-intervention data. SPSS Version 24 (IBM,
2016) was used to calculate the statistical results of this study.
Clinical Question 1. How does education about smoking cessation and the
provision of quick reference materials affect referrals to behavioral
counseling and prescribing smoking cessation pharmacotherapy with
healthcare providers at federally qualified healthcare centers in one
southeastern state within an eight-week period? The Wilcoxon Rank test was
run since the data was not normally distributed. A comparison of the preintervention compliance and post-intervention compliance showed an
improvement of 11% (Z=-2.09, p=.037). Health care providers improved in their
referrals of patients for smoking cessation treatment.
Clinical Question 2. What percentage of Self-Identified Current
Smokers (SICS) expressed a willingness to attempt quitting? Descriptive
statistics were run to determine the percentage of current smokers that have
expressed a willingness to attempt quitting during the Post Intervention Period.
Out of the identified tobacco users, 254 (61%) individuals were identified as
interested in or thinking about quitting. These results are similar to the Center for
Disease Control (2018) statistics (70%) who have expressed a desire to quit.
Clinical Question 3. What provider characteristics are associated with
increased smoking cessation referrals/treatment?
Age Variable. Spearman’s Rank-Order Correlation was run since the data
for age and improvement were not normally distributed. Data indicated that the
clinical question as to whether age and improvement were positively correlated
was not supported. There was no significant positive correlation between age and
improvement (r=.042, p=.891).
Years of Practice. Spearman’s Rank-Order Correlation analysis was run
since the data for the variable of years of practice and improvement were not
normally distributed. Data indicated that clinical question as to whether years of
practice and improvement were positively correlated was not supported. There

was no significant positive correlation between years of practice and improvement
(r=.127, p=.891).
Gender Variable. Spearman’s Rank-Order Correlation analysis was run
since the data for the variable of gender (binomial) and improvement was not
normally distributed. Data indicated that clinical question as to whether gender
and improvement were positively correlated was not supported. There was no
significant positive correlation between gender and improvement (r⸈=.058,
p=.851).
Race variable. Pearson’s Chi-square analysis was run used to test the
clinical question as to whether race and improvement were positively correlated.
There was no significant correlation between race and improvement (X2 .853, df
(2), p=.653).
Type of Provider. Pearson’s Chi-square analysis was run to test the
clinical question as to whether the type of provider and improvement were
positively correlated. There was no significant positive correlation between the
type of provider and improvement (X2=(3.494, df=2, p=.174).
Smoking Status. Pearson’s Chi-Square analysis was run to test the clinical
question as to whether the smoking status of the provider and improvement were
positively correlated. There was no significant positive correlation between
smoking status and improvement (X2=1.477, df=1, p=.224). It should be noted
that the sample did not include any current smokers, so the reliability of these
statistical results could be called into question.
As it relates to Clinical Question #1, 17.4% of all “eligible” candidates
received the “qualifying treatment” during the pre-intervention period. Following
the implementation of the intervention, 28.96% of all “eligible” candidates
received the “qualifying treatment”. This resulted in 34 more patients or an 11%
(Z=-2.09, p=.037) increase in the number of patients who have received the
“qualifying treatment” during the post-intervention period. The result for Clinical
Question #2 showed that the patients at the FQHC study clinic wished to quit
smoking at a similar rate to the national statistics produced by the CDC (2018).
The result for Clinical Question #3 showed no statistically significant positive
correlation for any of the healthcare provider characteristics to improvement in the
delivery of behavioral health and pharmacotherapy for smoking cessation
treatment.

Discussion

Limitations
The small size of the sample (n=13) and the necessity of using a
convenience sampling method reduced the ability to generalize the results of this
study (Kellar and Kelvin, 2013). The outcome dependent variable measuring the
difference in compliance with the provision of the “qualifying treatment” was
measured after 8 weeks secondary to the time limitations for an academic
translational project. The study could have been improved by examining the longterm effect of the multi-component intervention and the sustainability of the effect
of the interventions by measuring the level of compliance after 6 months. Because
the study only studied the impact on the healthcare provider in the delivery of the
smoking cessation treatment and not the impact on the patient’s smoking
abstinence, it did not result in the ability to determine the causal effect of the
delivery of the smoking cessation treatment. Another limitation of this study is
that during the intervention, instructions were given to where the documentation
of compliance should be entered into the electronic health record to optimize the
collection of that data. Since no instructions had been given before the
documentation during the pre-intervention period it may have resulted in a
decreased documentation of that delivery of that treatment.
One other factor that may have influenced the outcome of this study was
the lack of incorporation of physicians in the presentation of the educational
information. It might have provided some additional credibility to the information
from the perspective of other physician providers.
As the quick reference materials were being developed, the difficulty in
locating community resources for both behavioral health for smoking cessation
and smoking cessation classes became evident. It would have been more helpful
to have discovered these resources in our community, or at least been able to
ascertain those resources in neighboring communities.
Some data collection issues became evident following some investigation.
It was determined that not every medical assistant refreshed the data with each visit
regarding smoking status. Rather than simply addressing the demographic and
practice characteristics in the participant survey, it would have been more helpful
to develop a validated and reliable survey tool for the healthcare providers that
could determine their level of self-efficacy before and after the intervention.
Strengths
The strengths of this study include the fact that nearly all healthcare
providers voluntarily engaged as participants in the study without any attrition.
This demonstrated their interest in being a part of a quality improvement project
that would benefit their patients for the FQHC study clinic.
Future Research

As an extension of the current research, determine whether the statistically
significant impact of the educational training and the use of the reference materials
on the healthcare providers could be retained at six months. Research for the future
should focus on the impact of the use of interventions using web site applications
and text messaging for smoking cessation.
Summary
This translational clinical project provided answers to the clinical questions
studied. The data collected and analyzed for Clinical Question #1 during Phase II
(pre-intervention) and Phase III (post-intervention) demonstrated a statistically
significant (Z=-2.09, p=.037)
increase in compliance (provision of
“qualifying treatment” to “eligible” patients) following the multicomponent
intervention. A comparison of the pre-intervention compliance and postintervention compliance showed an improvement of 11%.
The data collected and analyzed for Clinical Question #2 during Phase III
(post-intervention) demonstrated that the current smokers at the FQHC study clinic
wished to quit smoking (61%). According to national statistics generated by the
CDC (2017), approximately 70% of current smokers wished to quit. These results
demonstrate that the desire to quit at the FQHC study clinic is similar to national
data.
The data collected and analyzed for Clinical Question #3 during Phase One
from the Healthcare Provider Survey (i.e. age, years of practice, race, provider
type, smoking status) was determined to have no positive correlation to the
healthcare provider improvement in compliance.

Conclusion
Significant progress has been made in the reduction of tobacco use in the United
States, but the smoking prevalence among the socially and economically
disadvantaged populations (i.e. individuals who are homeless, uninsured, LGBT,
and living with HIV) is significantly higher than the general population (CDC,
2018b). This results in this population carrying a disproportionate burden of
tobacco-related mortality and morbidity (CDC, 2018b). There is a cost-effective
and evidence-based treatment for tobacco use dependence (Fiore et al, 2008), but
the delivery by primary care providers to this population (Tyman, Bonevski, Paul,
and Bryant, 2014) is inconsistent. The study focused on determining whether the
delivery of a multicomponent intervention (i.e. educational session, quick
reference materials, and prompts in the electronic health records) to the health care
providers (n=13) at a federally qualified health care clinic would result in an
improvement of behavioral health referrals and pharmacotherapy for smoking
cessation. A retrospective review of the 8 weeks before the intervention, and 8

weeks after the intervention, was conducted to examine changes in provider
compliance with smoking cessation treatment guidelines. The data collected
suggested that there was a statistically significant increase in compliance with the
delivery of the qualifying treatment (Z=-2.09, p=.037) following the intervention.
The study also examined the relationship between demographic characteristics of
providers and improvement in provider compliance with no significant positive
correlations. Additional research is needed to examine whether this improvement
in compliance can be sustained at six months.
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Appendix A

Fact sheet about the health benefits of smoking
cessation
1. There are immediate and long-term health benefits of quitting for all
smokers.
Beneficial health changes that take place:
a. Within 20 minutes, your heart rate and blood pressure drop.
b. 12 hours, the carbon monoxide level in your blood drops to normal.
c. 2-12 weeks, your circulation improves and your lung function increases.

d.
e.
f.
g.
h.

1-9 months, coughing, and shortness of breath decrease.
1 year, your risk of coronary heart disease is about half that of a smoker's.
5 years, your stroke risk is reduced to that of a nonsmoker 5 to 15 years after quitting.
10 years, your risk of lung cancer falls to about half that of a smoker, and your risk of
cancer of the mouth, throat, esophagus, bladder, cervix, and pancreas decreases.
15 years, the risk of coronary heart disease is that of non-smokers.

2. People of all ages who have already developed smoking-related health
problems can still benefit from quitting.
Benefits in comparison with those who continued:
a. At about 30: gain almost 10 years of life expectancy.
b.
At about 40: gain 9 years of life expectancy.
c.
At about 50: gain 6 years of life expectancy.
d.
At about 60: gain 3 years of life expectancy.
After the onset of life-threatening disease: rapid benefit, people who quit smoking after having
a heart attack reduce their chances of having another heart attack by 50%

3. Quitting smoking decreases the excess risk of many diseases related to
second-hand smoke in children.
Quitting smoking decreases the excess risk of many diseases related to second-hand smoke in
children, such as respiratory diseases (e.g., asthma) and ear infections.

4. Others benefits.
Quitting smoking reduces the chances of impotence, having difficulty getting pregnant, having
premature births, babies with low birth weights and miscarriage.
Source: World Health Organization. (2014). Toolkit for Delivering the 5A’s and 5 R’s brief
tobacco intervention in primary care. Geneva, Switzerland; WHO Press. Retrieved from
https://apps.who.int/iris/bitstream/handle/10665/112835/9789241506953_eng.pdf;jsessionid=
7A3E873BD2237654BF8EF8EAD67425B1?sequence=1World Health Organization (2014.)

Appendix B

10 Key Recommendations
1. Tobacco dependence may require repetitive interventions, and
multiple quit attempts by smokers to accomplish smoking cessation.
The research supports that effective treatments are in existence and
they can improve the success rate of long-term smoking abstinence;
2. It is imperative that clinicians consistently identify tobacco use status
and then treat every tobacco user seen in their health setting;

3. Tobacco cessation treatments are effective for most populations.
Healthcare providers should assist every patient willing to make a quit
attempt to use the behavioral/counseling treatments and smoking
cessation medications that are recommended by this guideline;
4. Brief tobacco dependence treatment can be effective and should be
offered as a minimum;
5. Individual, group and telephone behavioral health counseling are
effective, and the more intense the treatment the more effective;
6. Numerous medications are available for treatment for tobacco
dependence; Clinicians should encourage the use of these medications
for all patients attempting to quit smoking, unless medically
contraindicated or where there is insufficient evidence of
effectiveness. The medications recommended that are proven to
increase long-term smoking abstinence: Bupropion SR, Nicotine
gum, nicotine inhaler, nicotine lozenge, nicotine nasal spray, nicotine
patch, and varenicline. They also recommended that certain
combinations can be effective with certain populations;
7. Counseling for smoking cessation and medications are effective either
by themselves. The most effective treatment is the combination of
counseling and smoking cessation pharmacotherapy. As clinicians we
should encourage all making a quit attempt to use both;
8. Telephone quitline counseling is effective with many different
population groups, and healthcare providers should ensure that
patients should have access to quitlines and promote its use;
9. If a current smoker of tobacco is unwilling to make a quit attempt
upon being advised to quit, the healthcare providers should use the
evidence-based motivational treatment to increase future quit
attempts;
10. The recommended treatment is effective and cost-effective and
recommended that insurance plans should ensure that the counseling
and smoking cessation pharmacotherapy recommended is a covered
benefit.
Source: Fiore, M.C. Jaen, C. R., Baker, T.B. et al. (2008). Treating Tobacco Use
and Dependence: 2008 Update. Clinical Practice Guideline. Rockville,
MD: U.S. Department of Health and Human Services. Public Health
Service. May 2008.

Appendix C
World Health Organization 5A’s Model for Individuals Motivated to Quit

5A’s

Action

Ask • Ask ALL your patients at
Systematically
every encounter if they
identify all
use tobacco and
tobacco users at
document it.
every visit.
• Make it part of your
routine.

Advise:
Persuade all
tobacco users
that they need
to quit

Strategies for implementation
• Tobacco use should be asked about in a friendly way –
it is not an accusation.
• Keep it simple, some sample questions may include:
– “Do you smoke cigarettes?”
– “Do you use any tobacco products?”
• Tobacco use status should be included in all medical
notes. Countries should consider expanding the vital
signs to include tobacco use or using tobacco use status
stickers on all patient charts or indicating tobacco use
status via electronic medical records.

• Urge every tobacco user to Advice should be:
quit in a clear, strong and • Clear – “It is important that you quit smoking (or using
personalized manner.
chewing tobacco) now, and I can help you.” “Cutting down
while you are ill is not enough.”
“Occasional or light smoking is still dangerous.”
• Strong – “As your doctor, I need you to know that quitting
smoking is the most important thing you can do to protect
your health now and in the future. We are here to help
you.”
• Personalized – Tie tobacco use to:
− Demographics: For example, women may be more likely
to be interested in the effects of smoking on fertility than
men.
− Health concerns: Asthma sufferers may need to hear
about the effect of smoking on respiratory function,
while those with gum disease may be interested in the
effects of smoking on oral health. “Continuing to smoke
makes your asthma worse, and quitting may
dramatically improve your health.”
− Social factors: People with young children may be
motivated by information on the effects of second-hand
smoke, while a person struggling with money may want
to consider the financial costs of smoking. “Quitting
smoking may reduce the number of ear infections your
child has.”
In some cases, how to tailor advice for a particular patient
may not always be obvious. A useful strategy may be to
ask the patient: − “What do you not like about being a
smoker?”
The patient’s answer to this question can be built upon by
you with more detailed information on the issue raised.
− Example:
Doctor: “What do you not like about being a smoker?”
Patient: “Well, I don’t like how much I spend on tobacco.”
Doctor: “Yes, it does build up. Let’s work out how much
you spend each month. Then we can think about what
you could buy instead!”

Assess:
Determine
readiness to
make a quit
attempt

Ask two questions in relation
to “importance” and “selfefficacy”:
1. “Would you like to be a
nontobacco user?”
“Do you think you have a
chance of quitting
successfully?”

Any answer to either question that is Unsure or No indicates
that the tobacco user is NOT ready to quit. In these cases,
you should deliver the 5 R’s intervention.
Question 1
Unsure No
Question 2
Unsure No
If the patient is ready to go ahead with a quit attempt you
can move onto Assist and Arrange steps.

Assist - Help
the patient with
a quit plan

• Help the patient develop a •Use the STAR method to facilitate and help your patient to
develop a quit plan:
quit plan
− Set a quit date ideally within two weeks.
• Provide practical
− Tell family, friends, and coworkers about quitting, and ask
counseling
for support.
• Provide intra-treatment
− Anticipate challenges to the upcoming quit attempt.
social support
− Remove tobacco products from the patient’s environment
• Provide supplementary
and make the home smoke free.
materials, including
•Practical counseling should focus on three elements:
information on quitlines
− Help the patient identify the danger situations (events,
and other referral
internal states, or activities that increase the risk of smoking
resources
or relapse).
− Help the patient identify and practice cognitive and
Recommend the use of
behavioral coping skills to address dangerous situations.
approved medication if
− Provide basic information about smoking and quitting
needed
•Intra-treatment social support includes:
− Encourage the patient in the quit attempt
− Communicate caring and concern
− Encourage the patient to talk about the quitting process
•Make sure you have a list of existing local tobacco
cessation services (quitlines, tobacco cessation clinics, and
others) on hand for providing information whenever the
patient inquiries about them.
•The support given to the patient needs to be described
positively but realistically.

Arrange Schedule
follow-up
contacts or a
referral to
specialist
support

Arrange - Schedule followup contacts or a referral to
specialist support

When: The first follow up contact should be arranged during
the first week. A second follow up contact is recommended
within one month after the quit date.
•How: Use practical methods such as telephone, personal
visit and mail/ email to do the follow-up. Following up with
patients is recommended to be done through teamwork if
possible.
•What:
For all patients:
− Identify problems already encountered and anticipate
challenges.
− Remind patients of available extra-treatment social
support.
− Assess medication use and problems. − Schedule the
next follow up contact.
For abstinent patients:
− Congratulate them on their success.
For patients who have used tobacco again:
− Remind them to view relapse as a learning experience.
− Review circumstances and elicit recommitment.
− Link to more intensive treatment if available.

Source: World Health Organization. (2014). Toolkit for Delivering the 5A’s and
5 R’s brief tobacco intervention in primary care. Geneva, Switzerland; WHO
Press. Retrieved from
https://apps.who.int/iris/bitstream/handle/10665/112835/9789241506953_eng.pd
f;jsessionid=7A3E873BD2237654BF8EF8EAD67425B1?sequence=1.

Appendix D
World Health Organization 5R’s Model for Individuals Not Motivated to
Quit
5R’s

Strategies for implementation

Relevance Encourage the patient to indicate how quitting is
personally relevant to him or her.

Risks

Example
HCP: “How is quitting most personally
relevant to you?”

Motivational information has the greatest impact if it
is relevant to a patient’s disease status or risk,
family or social situation (e.g. having children in the
home), health concerns, age, sex, and other
important patient characteristics (e.g. prior quitting
experience, personal barriers to cessation).

P: “I suppose smoking is bad for my
health.”

Encourage the patient to identify potential negative
consequences of tobacco use that are relevant to
him or her.
Examples of risks are:
•
Acute risks: shortness of breath,
exacerbation of asthma, increased risk of
respiratory infections, harm to pregnancy,
impotence, and infertility.
•
Long-term risks: heart attacks and
strokes, lung and other cancers (e.g. larynx, oral
cavity, pharynx, esophagus), chronic obstructive
pulmonary diseases, osteoporosis, long-term
disability, and need for extended care.

HCP: “What do you know about the risks
of smoking to your health? What
particularly worries you?” ¨
P: “I know it causes cancer. That must be
awful.”
HCP: “That’s right – the risk of cancer is
many times higher among smokers.”

•
Environmental risks: increased risk of
lung cancer and heart disease in spouses;
increased risk for low birth-weight, sudden infant
death syndrome, asthma, middle ear disease,
and respiratory infections in children of smokers.
Rewards

Ask the patient to identify potentially relevant
benefits of stopping tobacco use.
Examples of rewards could include:
− improved health;
− food will taste better;
− improved sense of smell;
− saving money;
− feeling better about oneself;
− home, car, clothing, and breath will smell better;
− setting a good example for children and
decreasing the likelihood that they will smoke;
− having healthier babies and children;
− feeling better physically;
− performing better in physical activities.
− improved appearance, including reduced
wrinkling/aging of the skin and whiter teeth.

HCP: “Do you know how stopping
smoking would affect your risk of cancer?”
P: “I guess it would be more successful if I
quit.”
HCP: “Yes, and it doesn’t take long for the
risk to decrease. But it’s important to quit as
soon as possible.”

Source: World Health Organization. (2014). Toolkit for Delivering the 5A’s and
5 R’s brief tobacco intervention in primary care. Geneva, Switzerland; WHO
Press. Retrieved from
https://apps.who.int/iris/bitstream/handle/10665/112835/9789241506953_eng.pdf;j
sessionid=7A3E873BD2237654BF8EF8EAD67425B1?sequence=1.
Appendix E
United States Preventive Services Task Force Recommendations
Adults who The USPSTF recommends that clinicians ask all
are not
adults about tobacco use, advise them to stop using
A
pregnant
tobacco, and provide behavioral interventions and the
U.S. Food and Drug Administration (FDA)-approved
pharmacotherapy for cessation to adults who use
tobacco.
Pregnant
The USPSTF recommends that clinicians ask all
Women
pregnant women about tobacco use, advise them to
A
stop using tobacco, and provide behavioral
interventions for cessation to pregnant women who
use tobacco.
Pregnant
The USPSTF concludes that the current evidence is
Women
insufficient to assess the balance of benefits and
I
harms of pharmacotherapy interventions for tobacco
cessation in pregnant women
All adults
The USPSTF concludes that the current evidence is
including
insufficient to recommend electronic nicotine delivery
I
pregnant
systems (ENDS) for tobacco cessation in adults,
women
including pregnant women.
Source: U.S. Preventive Services Task Force. (2015). Final Update Summary:
Tobacco Smoking Cessation in Adults, Including Pregnant Women: Behavioral
and Pharmacotherapy Interventions. U.S. Preventive Services Task Force.
September 2015. Retrieved from
https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummary
Final/tobacco-use-in-adults-and-pregnant-women-counseling-and-interventions1

Appendix F
Consensus Decision Pathway on Tobacco Cessation Treatment

Source: Barua, R. S. and Rigotti, N. A., et al., (2018). ACC expert
consensus decision pathway on tobacco cessation treatment. Taken from:
https://www.sciencedirect.com/science/article/pii/S0735109718388594?vi
a%3Dihub

APPENDIX G
INFORMED CONSENT
I, _________________________________________________, agree to
participate in the research “Effect of an Intervention to Improve Smoking
Cessation treatment in a Federally Qualified Healthcare Clinic”, which is being
conducted by Shirley A. Camp, JD, MSN, FNP-C, who can be reached at (478)
471-2979 or shirley.camp@bobcats.gcsu.edu. I understand that my participation
is voluntary; I can withdraw my consent at any time. If I withdraw my consent,
my data will not be used as part of the study and will be destroyed.
The following points have been explained to me:
1.

2.

The purpose of this study is an interdisciplinary effort to increase
access to smoking cessation treatment for the underserved population
at XXXXXXXXXXXXX with the provision of a smoking cessation
treatment educational intervention that is individualized for a federally
qualified healthcare clinic population. In addition, participants will be
provided with quick reference materials that will provide information
about behavioral healthcare community resources for smoking
cessation and the efficacy and cost of smoking cessation
pharmacotherapy.
The procedures are as follows: you will be asked to listen to an
educational intervention conducted by the principal investigator and
complete a simple demographic and practice survey. Once you have
agreed to participate and signed the informed consent, data will be
retrieved from the electronic health record of any patient that you have
seen and treated in the previous eight (8) weeks who are self-identified
smokers. The determination will be made if they indicated a
willingness to quit smoking, and if so, whether they were referred to
behavioral counseling (including the Georgia Smoking Quitline) or
given prescriptions for smoking cessation pharmacotherapy.
Following the educational intervention, the healthcare provider will be
expected to implement the recommended treatment and documentation
for smoking cessation treatment for all patients that express an interest
in quitting tobacco use. For a period of eight (8) weeks following the
educational intervention, the same data will be collected to determine
if there has been an increase in the percentage of behavioral health
referrals and/or smoking cessation pharmacotherapy prescriptions.

3.

4.

5.

6.

7.

8.

9.

Your name will be connected to your demographic/practice survey but
will be secured and maintained in the sole possession of the Principal
Investigator. Following one year, the survey will be confidentially
destroyed. Two reports will be generated for the PI per participant by
the computer technician with the aggregate patient data. No patient
names or nor patient medical record numbers will be provided to PI.
No FCPC administration will have access to any of this providerspecific information. Any dissemination of this information for
publication will be provided only in the aggregate and without mention
of provider names or patient names. Any patient files will be
protected by a password-protected file, and a laptop which is placed in
a locked secure location, unless in the immediate presence of the
principal investigator.
You will be asked to sign two identical consent forms. You must
return one form to the investigator before the study begins, and you
may keep the other consent form for your records.
You may find that some questions are invasive or personal. If you
become uncomfortable answering any questions, you may cease
participation at that time.
This research project is being conducted because of its potential
benefits, either to individuals or to humans in general. The expected
benefits of this study include 1) improving your understanding of the
most recent evidence-based smoking cessation treatment that is
individualized for the patient population that is treated at a federally
qualified healthcare clinic; 2) improving the percentage of selfidentified patients that are referred to behavioral counseling for
smoking cessation; 3) improving the percentage of patients who are
self-identified smokers (SIS) that receive smoking cessation
pharmacotherapy (if eligible). Because of the established effectiveness
of these two interventions, the resulting increase in smoking quit rates,
and abstinence has a substantial economic and health outcomes effect.
You are not likely to experience physical, psychological, social, or
legal risks beyond those ordinarily encountered in daily life or during
the performance of routine examinations or tests by participating in
this study.
Your responses will be confidential and will not be released in any
individually identifiable form without your prior consent unless
required by law.
The investigator will answer any further questions about the research
should you have them now or in the future (see above contact
information).

10.

In addition to the above, further information, including a full
explanation of the purpose of this research, will be provided after the
research project has been completed on request.
By signing and returning this form, you are acknowledging that you
are 18 years of age or older.

11.

Signature of Investigator

Date

Signature of Participant

Date

Research at Georgia College involving human participants is carried out under the
oversight of the Institutional Review Board. Address questions or problems
regarding these activities to Dr. Whitney Heppner, GC IRB Chair, CBX 090, GC,
email: irb@gcsu.edu; phone: (478) 445-0870.

Appendix H

Effect of an Intervention to Improve Smoking Cessation
Treatment in a Federally Qualified Healthcare Clinic
Healthcare Provider Participant Survey (Phase I)
Participant Name ______________________________________
Last Name

Type of Provider (Circle appropriate answer)
MD
NP
PA

First Name

Age (Circle appropriate answer) (Years)
18-29
30-39
40-49
50-59
60-69
70 or above
Race (Circle appropriate answer)
Caucasian
African-American
Asian
Other
Gender (Circle appropriate answer)
Female
Male
Years of Practice (Circle appropriate answer)
0-2 years of practice
3-5 years of practice
6-10 years of practice
11-19 years of practice
20 or above years of practice

Smoking Status of Provider
Current
Former
Never

After this data was received, the participants were contacted and requested that they
provide their actual age and the years of practice on July 25, 2018, for more
accurate statistical purposes.

Appendix I
Effect of an Intervention to Improve Smoking Cessation Treatment in a
Federally Qualified Healthcare Clinic
Educational Program for Healthcare Providers
Identification of the Problem
Smoking Prevalence Rate at FQHC Study Clinic
International, National and State Goals for Tobacco Control
Primary Care Providers Delivery
Study Design
Clinical Questions
Purpose of the Study
Participation in Study
Background information
Health Risks and Economic Costs Associated with Tobacco Use
Benefits of tobacco cessation
Prevalence among Vulnerable populations
Literature Review
Clinical Guidelines for Tobacco Use Dependence Treatment
Key Recommendations
Review of 5 A’s ad 5 R’s Model
USPSTF Recommendations for Tobacco Use Treatment
American College of Cardiology Decision Tree
Multicomponent Intervention Can Improve Delivery of Smoking
Cessation Treatment

Identification of Barriers and Factors in Delivery of Smoking
Cessation Treatment
Presentation by Executive Director for Georgia Smoking Quit Line
Presentation by Director of Community Smoking Cessation Classes
Required EHR Documentation to Determine Compliance for Study
Qualified Behavioral Health Referrals and Pharmacotherapy
for Smoking Cessation Treatment
Review of Quick Reference Materials
Copy of Clinical Guidelines for Tobacco Use Dependence
Efficacy, Issues, and Costs Associated with Smoking Cessation
Pharmacotherapy
Insurance Coverage/Costs Associated with Behavioral Health
Referrals and Pharmacotherapy for Smoking Cessation
Impact of the Patient Care and Affordability Care Act
(2010)
Available Coupons for Smoking Cessation
Pharmacotherapy

